...the open-label, U.S. trial include safety and pharmacokinetics. MAT2203 is a lipid-crystal nanoparticle formulation of amphotericin B... ...Bedminster, N.J. Product: MAT2203 (CAmB) Business: Infectious Molecular target: Ergosterol Description: Lipid-crystal nanoparticle formulation of amphotericin B...
...of VL. There are two marketed therapies for VL: AmBisome amphotericin b, a unilamellar formulation of amphotericin B... ...other forms of the disease; and iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF) has ICo-009 , oral amphotericin B...
...on its development plans for MAT2203 this quarter. MAT2203 is a lipid-crystal nanoparticle formulation of amphotericin B... ...Product: CAmB ( MAT2203 ) Business: Infectious Molecular target: Ergosterol Description: Lipid-crystal nanoparticle formulation of amphotericin B...